Gastroesophageal Junction Cancer

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki for treatment of HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

The FDA granted orphan drug designation to APX005M for the treatment of three gastrointestinal cancer types, according to the agent’s manufacturer.

The FDA granted orphan drug designation to CT041 for the treatment of adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.

The FDA granted fast track designation to DKN-01 for the treatment of certain patients with gastric cancer or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Nivolumab plus chemotherapy increased PFS and OS compared with chemotherapy alone among previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, study results showed.

The FDA granted orphan drug designation to DKN-01 for the treatment of gastric or gastroesophageal junction cancers.

The FDA granted fast track designation to several therapies in development for hematology or oncology indications.

The FDA granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.